Saponin Nanoparticle Adjuvants Incorporating Toll-Like Receptor Agonists Drive Distinct Immune Signatures and Potent Vaccine Responses

Ben S. Ou,Julie Baillet,Maria Victoria Filsinger Interrante,Julia Z Adamska,Xueting Zhou,Olivia Saouaf,Jerry Yan,John Klich,Carolyn K Jons,Emily Meany,Adian S Valdez,Lauren Carter,Bali Pulendran,Neil P King,Eric Appel

DOI: https://doi.org/10.1101/2023.07.16.549249

2024-06-27

Abstract:Over the past few decades, the development of potent and safe immune-activating adjuvant technologies has become the heart of intensive research in the constant fight against highly mutative and immune evasive viruses such as influenza, SARS-CoV-2, and HIV. Herein, we developed a highly modular saponin-based nanoparticle platform incorporating toll-like receptor agonists (TLRas) including TLR1/2a, TLR4a, TLR7/8a adjuvants and their mixtures. These various TLRa-SNP adjuvant constructs induce unique acute cytokine and immune-signaling profiles, leading to specific Th-responses that could be of interest depending on the target disease for prevention. In a murine vaccine study, the adjuvants greatly improved the potency, durability, breadth, and neutralization of both COVID-19 and HIV vaccine candidates, suggesting the potential broad application of these adjuvant constructs to a range of different antigens. Overall, this work demonstrates a modular TLRa-SNP adjuvant platform which could improve the design of vaccines for and dramatically impact modern vaccine development.

Bioengineering

What problem does this paper attempt to address?

This paper aims to address the following key issues: ### Research Background and Objectives - **Current Challenges**: Developing efficient and safe immune-activating adjuvant technologies has become a research focus in combating highly variable viruses that can evade the immune system, such as influenza, SARS-CoV-2 (COVID-19), and HIV. - **Limitations of Existing Technologies**: - Traditional vaccines (such as live attenuated vaccines or inactivated virus vaccines) have complex production processes and potential safety risks. - Protein subunit vaccines, while having advantages in safety, cost-effectiveness, scalability, and manufacturing feasibility, rely on adjuvants to enhance the magnitude and durability of the immune response. ### Solution - **Development of New Adjuvants**: This study developed a highly modular saponin nanoparticle platform capable of integrating multiple Toll-like receptor agonists (TLRa), including adjuvants targeting TLR1/2, TLR4, TLR7/8, and their mixtures. - **Achieving Objectives**: These adjuvant combinations can induce unique acute cytokine and immune signaling profiles, thereby guiding specific Th cell responses, which may be crucial for preventing different diseases. ### Key Findings - **Enhanced Vaccine Efficacy**: In mouse vaccine studies, these adjuvants significantly improved the potency, durability, breadth, and neutralizing ability of COVID-19 and HIV vaccine candidates, suggesting that these adjuvant constructs could be widely applicable to various antigens. - **Regulation of Immune Responses**: By modulating the combinations of different Toll-like receptor agonists, it is possible to regulate the types of Th cell responses, thereby customizing vaccine responses according to the needs of the target disease. ### Summary In summary, this paper aims to improve vaccine design by developing a modular Toll-like receptor agonist-saponin nanoparticle adjuvant platform, which is expected to have a significant impact on modern vaccine development.

Saponin Nanoparticle Adjuvants Incorporating Toll-Like Receptor Agonists Drive Distinct Immune Signatures and Potent Vaccine Responses

A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2

A universal TLR7-nanoparticle adjuvant promotes broad immune responses against heterologous strains of Influenza and SARS-CoV-2

Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine

Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release

Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune response

A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity

Tuning the immune response: sulfated archaeal glycolipid archaeosomes as an effective vaccine adjuvant for induction of humoral and cell-mediated immunity towards the SARS-CoV-2 Omicron variant of concern

Adjuvant Activities of Saponins from Traditional Chinese Medicinal Herbs.

Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses

Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen

The synthesis and preliminary immunological evaluation of a dual-adjuvant SARS-CoV-2 RBD vaccine: Covalent integration of TLR7/8 and iNKT cell agonists

A Novel Polymer Nanoparticle Polydimethyl Diallyl Ammonium Chloride as An Adjuvant Enhances the Immune Response of SARS-CoV-2 Subunit Vaccine

A Polymer-Based Antigen Carrier Activates Two Innate Immune Pathways for Adjuvant-Free Subunit Vaccines

Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern

Nanoparticle-Conjugated Toll-Like Receptor 9 Agonists Improve the Potency, Durability, and Breadth of COVID-19 Vaccines

Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines

Novel sialoglycan linkage for constructing adjuvant-protein conjugate as potent vaccine for COVID-19

Strategic Development of a Self-Adjuvanting SARS-CoV-2 RBD Vaccine: from Adjuvant Screening to Enhanced Immunogenicity with a Modified TLR7 Agonist

Zeolitic imidazolate frameworks activate endosomal Toll-like receptors and potentiate immunogenicity of SARS-CoV-2 spike protein trimer

Dose-dependent regulation of immune memory responses against HIV by saponin monophosphoryl lipid A nanoparticle adjuvant